Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

p> patients. Preliminary data from this trial will be presented at the

American Society of Clinical Oncology meeting in June.

Genzyme is developing a new filing for the adult AML indication in

Europe. This follows its withdrawal of Bioenvision's marketing

application, which, as expected, an advisory committee deemed

insufficient to support approval. Genzyme expects to make a new

submission as early as the fourth quarter of this year that will

include a more robust data package from Genzyme sponsored studies.

Alemtuzumab for multiple sclerosis

-- Final, three-year efficacy and safety data from the Phase 2 trial

comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment

of relapsing-remitting multiple sclerosis were presented last week

during a scientific platform session at the American Academy of

Neurology meeting by Dr. Alasdair Coles. These results confirm all

trends observed in the one- and two-year interim analyses. The two

ongoing Phase 3 trials further examining the efficacy and safety of

alemtuzumab for the treatment of MS are progressing. These two studies

are currently enrolling patients at sites in the United States, Europe,

Latin America and Australia. Genzyme believes that alemtuzumab has the

potential to be the best therapy in a market for MS drugs that is

projected to reach $8-9 billion annually when the treatment is expected

to be ready for launch in 2011-2012. Alemtuzumab is being developed in

collaboration with Bayer Schering Pharma AG, Germany.

Genz-112638 for Gaucher disease

-- Genzyme is making excellent progress in developing the small molecule

Genz-112638, a novel oral therapy intended for the treatment of Gaucher

disease. Initial results released one year ago for the first group of

stud
'/>"/>

SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ... navigate and understand both the current standard of care ...
(Date:1/15/2014)... IPSWICH, England , January 15, 2014 ... whether technology developed to win races on the Formula ... obesity.  This unique healthcare collaboration between McLaren Applied Technologies ... academics at University Campus Suffolk is being funded by ... inspired by equipment used to collect data about the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS ... enhancement to its Online Web Portal for Life Science ... have the ability to specify the subject matter of ... 50 life science sub-domains. This will help reduce time-to-delivery ... scientific fields, and decrease the likelihood of error. , ...
(Date:1/15/2014)... 15, 2014 TaiGen Biotechnology Company, Limited ... exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... ) in the Russian Federation ... members of the Commonwealth Independent States (CIS). Nemonoxacin is ... infections including those caused by drug-resistant bacteria. Under ...
Breaking Biology Technology:Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4
... Minimally Invasive Treatment of Bone Fractures Achieves Significant ... Feb. 23 IlluminOss Medical Inc., a medical ... Stabilization System for orthopedic surgery, today announced that ... Registration issued by BSI (British Standards Institute). ...
... February 23 Health Robotics and Can-Med,today ... agreement whereby Can-Med,has acquired the exclusive distribution ... Georgia, Kazakhstan, Uzbekistan, Azerbaijan,Iran, Mongolia, Turkmenistan, Kyrgyzstan, ... only automated, point-of-care-distributed, and fail-safe,robotic system for ...
... YORK, Feb. 23 NeoStem, Inc. (NYSE Alternext ... processing and long-term storage of adult stem cells ... signed a license agreement to obtain the exclusive ... applications for cosmetic facial and body procedures and ...
Cached Biology Technology:IlluminOss Medical Receives ISO 13485 Certification 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 2NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies 3
(Date:4/15/2014)... LIVERMORE, Calif. Zero-emission hydrogen fuel cell systems soon could ... industrial settings at lower costs and with faster refueling ... Sandia National Laboratories and Hawaii Hydrogen Carriers (HHC). , ... solid-state hydrogen storage system that can refuel at low ... to charge a battery-powered forklift, giving hydrogen a competitive ...
(Date:4/15/2014)... research published in the March/April 2014 issue of ... shows whey protein, either as a supplement combined ... or weight-maintenance diet, may provide men and women benefits ... 14 randomized controlled trials with a total of 626 ... that used whey protein to replace calories in the ...
(Date:4/14/2014)... you,re over 24 years of age you,ve already reached ... according to a new Simon Fraser University study. ... professor Mark Blair, Thompson,s thesis supervisor, and Andrew Henrey, ... news in a just-published PLOS ONE Journal ... science experiments to rest on big data, the trio ...
Breaking Biology News(10 mins):Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4New meta-analysis builds on the power of whey protein for improved body composition 2New meta-analysis builds on the power of whey protein for improved body composition 3Study says we're over the hill at 24 2
... cells are the body,s mechanics, repairing damaged tissues and organs. ... of cell in the body, scientists believe they hold the ... scientists from the University of Victoria have found a new ... for regenerative medicine. "Cells in your body grow and ...
... Md. (March 1, 2012)The American Physiology Society (APS) has announced ... experimental animals and the sex or gender of humans used ... 13 peer-reviewed journals. This notable requirement for all research study ... be presented in an editorial, " In Pursuit of Scientific ...
... PULLMAN, Wash.A Washington State University researcher has demonstrated that a ... just an exposed animal but the next three generations of ... the compounds change the way genes turn on and offthe ... Skinner and expanded on in the current issue of the ...
Cached Biology News:APS issues new policy requiring identification of sex or gender in reporting scientific research 2APS issues new policy requiring identification of sex or gender in reporting scientific research 3Effects of environmental toxicants reach down through generations 2
... Fluoroskan Ascent FL ... fluorometric and luminometric measurement ... long list of advanced ... and Luminoskan Ascent. Fluoroskan ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... Roche Applied Science, which pioneered the blending ... High Fidelity and Expand Long Template PCR ... PCR System the first product of ... This new blend combines Taq DNA Polymerase ...
... 13 5'G AATTC3' 3'CTTAA G5' Inactivation Conditions: Heat ... precipitation. Storage Conditions: 10mM Tris-HCl (pH 7.5), 100mM ... 0.01% BSA, 50% glycerol. Shipping and Storage: Shipped ... One unit is defined as the amount of ...
Biology Products: